Last updated on April 2019

AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia


Brief description of study

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia

Detailed Study Description

This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory multiple myeloma and subjects with relapsed or refractory acute myeloid leukemia The study will be conducted in four parts.

Clinical Study Identifier: NCT02675452

Find a site near you

Start Over

Research Site

Chicago, IL United States
  Connect »

Research Site

Boston, MA United States
  Connect »

Research Site

Hackensack, NJ United States
  Connect »

Research Site

Parkville, Australia
  Connect »

Research Site

Duarte, CA United States
  Connect »

Research Site

New Orleans, LA United States
  Connect »

Research Site

Houston, TX United States
  Connect »

Research Site

Salt Lake City, UT United States
  Connect »

Research Site

Sacramento, CA United States
  Connect »

Research Site

Toronto, ON Canada
  Connect »

Research Site

Calgary, AB Canada
  Connect »

Research Site

Würzburg, Germany
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.